Patents & Trials Tracker

The R&D paper trail: clinical-trial registrations as sponsors file them, matched to tickers where the sponsor is public, and the full US patent-grant record behind them, published as open data.

Most active sponsors · 90 days

1National Cancer Institute (NCI)400 studies

2AstraZenecaAZN167 studies

3Janssen Research & Development, LLC146 studies

4Merck Sharp & Dohme LLCMRK131 studies

5M.D. Anderson Cancer Center122 studies

6National Institute of Allergy and Infectious Diseases (NIAID)120 studies

7Eli Lilly and CompanyLLY108 studies

8Novartis PharmaceuticalsNVS102 studies

9PfizerPFE75 studies

10VA Office of Research and Development71 studies

The patent-grant corpus

9,434,703

US patent grants from 1976 through 2025, assignee-matched to tickers, refreshed from the USPTO's quarterly bulk releases. Nine million rows don't belong in a web table, the full corpus ships as open, year-sharded data.

Get the data →About the pipeline

FDA drug-application events are in the same pipeline and join this page once that feed starts publishing rows.

SponsorStudyPhaseStatusConditionsUpdatedRegistry

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Natural History of Thyroid Function DisordersNCT00001159·recruitingHyperthyroidism, Hypothyroidism2026-09-04

National Institute of Allergy and Infectious Diseases (NIAID)Genetic Analysis of Immune DisordersNCT00001467·recruitingDOK 8, STAT12026-09-04

National Institute of Neurological Disorders and Stroke (NINDS)Evaluation of Patients With HAM/TSPNCT00001778·recruitingHTLV-I Infection, Tropical Spastic Paraparesis2026-09-04

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Evaluation of Patients With Liver DiseaseNCT00001971·recruitingHepatitis D, Hepatitis C2026-09-04

National Human Genome Research Institute (NHGRI)Natural History Study of Smith-Magenis SyndromeNCT00013559·completedSmith-Magenis Syndrome (SMS)2026-09-04

National Institute of Environmental Health Sciences (NIEHS)Adult and Juvenile MyositisNCT00017914·recruitingDermatomyositis, Polymyositis2026-09-04

National Institute of Allergy and Infectious Diseases (NIAID)Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous SystemNCT00794352·recruitingCentral Nervous System Disease, Multiple Sclerosis2026-09-04

Washington University School of MedicineHealthy Volunteers Study of the Effects of Olanzapine and ZiprasidoneNCT00910988NAcompletedHyperglycemia, Hyperlipidemia2026-09-04

National Cancer Institute (NCI)Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological StudiesNCT01109394·recruitingSarcoma, Endocrine Tumors2026-09-04

VA Office of Research and DevelopmentColonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)NCT01239082NAactive not recruitingColorectal Cancer2026-09-04

National Cancer Institute (NCI)BRCA Mutations in LatinasNCT01251900·completedBreast Neoplasms2026-09-04

National Cancer Institute (NCI)Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionNCT01366144PHASE1active not recruitingBreast Carcinoma, Carcinoma of Unknown Primary2026-09-04

National Institute of Environmental Health Sciences (NIEHS)Blood Vessel StudyNCT01524549·completedCardiovascular Disease2026-09-04

Boston Scientific CorporationBSXPatient Retrospective Outcomes (PRO)NCT01550575·recruitingChronic Pain2026-09-04

Massachusetts General HospitalFOLFIRINOX + RT for Pancreatic CancerNCT01591733PHASE2completedPancreatic Cancer2026-09-04

National Cancer Institute (NCI)Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaNCT01695941PHASE1active not recruitingRecurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma2026-09-04

National Cancer Institute (NCI)Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent NeuroblastomaNCT01711554PHASE1active not recruitingRecurrent Neuroblastoma, Refractory Neuroblastoma2026-09-04

University of CincinnatiImprovement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid DynamicsNCT01719016·active not recruitingCoronary Artery Disease2026-09-04

Centre Hospitalier Departemental VendeeImpact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and CatecholaminesNCT01802099NAcompletedAcute Respiratory Failure, Shock2026-09-04

St. Anna KinderkrebsforschungAllogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaNCT01949129PHASE2/PHASE3recruitingAcute Lymphoblastic Leukaemia2026-09-04

Oregon Health and Science UniversityFunctional and Structural Imaging for GlaucomaNCT01957267·recruitingGlaucoma2026-09-04

Medical College of WisconsinMR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic CancerNCT01972919PHASE2completedUnresectable Pancreatic Cancer2026-09-04

Children's Hospital Medical Center, CincinnatiDonor-Derived Viral Specific T-cells (VSTs)NCT02048332PHASE1/PHASE2recruitingAllogeneic Stem Cell Transplant, Viral Infection2026-09-04

M.D. Anderson Cancer CentermTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianNCT02208375PHASE1active not recruitingBRCA1 Mutation Carrier, BRCA2 Mutation Carrier2026-09-04

Alexion Pharmaceuticals, Inc.Registry of Patients With HypophosphatasiaNCT02306720·enrolling by invitationHypophosphatasia (HPP)2026-09-04

Trials are sponsor-declared registry facts from ClinicalTrials.gov (API v2), a registration is not a result. Patent counts come from PatentsView bulk grant data on the USPTO Open Data Portal. Sponsor and assignee ticker matches are best-effort. Information only, not financial advice.